全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
PLOS ONE  2013 

Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing Antibodies

DOI: 10.1371/journal.pone.0064595

Full-Text   Cite this paper   Add to My Lib

Abstract:

Dengue is a mosquito-borne viral disease with a global prevalence. It is caused by four closely-related dengue viruses (DENVs 1–4). A dengue vaccine that can protect against all four viruses is an unmet public health need. Live attenuated vaccine development efforts have encountered unexpected interactions between the vaccine viruses, raising safety concerns. This has emphasized the need to explore non-replicating dengue vaccine options. Virus-like particles (VLPs) which can elicit robust immunity in the absence of infection offer potential promise for the development of non-replicating dengue vaccine alternatives. We have used the methylotrophic yeast Pichia pastoris to develop DENV envelope (E) protein-based VLPs. We designed a synthetic codon-optimized gene, encoding the N-terminal 395 amino acid residues of the DENV-2 E protein. It also included 5’ pre-membrane-derived signal peptide-encoding sequences to ensure proper translational processing, and 3’ 6× His tag-encoding sequences to facilitate purification of the expressed protein. This gene was integrated into the genome of P. pastoris host and expressed under the alcohol oxidase 1 promoter by methanol induction. Recombinant DENV-2 protein, which was present in the insoluble membrane fraction, was extracted and purified using Ni2+-affinity chromatography under denaturing conditions. Amino terminal sequencing and detection of glycosylation indicated that DENV-2 E had undergone proper post-translational processing. Electron microscopy revealed the presence of discrete VLPs in the purified protein preparation after dialysis. The E protein present in these VLPs was recognized by two different conformation-sensitive monoclonal antibodies. Low doses of DENV-2 E VLPs formulated in alum were immunogenic in inbred and outbred mice eliciting virus neutralizing titers >1:1200 in flow cytometry based assays and protected AG129 mice against lethal challenge (p<0.05). The formation of immunogenic DENV-2 E VLPs in the absence of pre-membrane protein highlights the potential of P. pastoris in developing non-replicating, safe, efficacious and affordable dengue vaccine.

References

[1]  Swaminathan S, Khanna N (2009) Dengue: recent advances in biology and current status of translational research. Curr Mol Med 9: 152–173.
[2]  Swaminathan S, Batra G, Khanna N (2010) Dengue vaccines: state of the art. Expert Opin Ther Patents 20: 819–835.
[3]  Gubler DJ, Kuno G, Markoff L (2007) Flaviviruses. In: Knipe DM, Howley PM, editors-in-chief. Fields Virology, 5th edition. Philadelphia, PA: Wolters Kluwer and Lippincott Williams & Wilkins. pp.1153–1252.
[4]  WHO Factsheet No117 (2012) Dengue and dengue haemorrhagic fever. Available:http://www.who.int/mediacentre/factsheet?s/fs117/en/. Accessed 2013 Jan 28.
[5]  Innis BL (1997) Antibody responses to dengue virus infection. In: Gubler DJ, Kuno G, editors. Dengue and Dengue Hemorrhagic Fever. Wallingford: CAB International. pp. 221–243.
[6]  Guzmán MG, Kouri G, Valdés L, Bravo J, Vázquez S, et al. (2002) Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Pan Am J Public Health 11: 223–227.
[7]  Halstead SB (2003) Neutralization and antibody dependent enhancement of dengue viruses. Adv Virus Res 60: 421–467.
[8]  Schmitz J, Roehrig J, Barrett A, Hombach J (2011) Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 29: 7276–7284.
[9]  Coller BAG, Clements DE (2011) Dengue vaccines: progress and challenges. Curr Opin Immunol 23: 391–398.
[10]  Thomas SJ, Endy TP (2011) Vaccines for the prevention of dengue: development update. Hum Vaccines 7: 674–684.
[11]  Edelman R (2011) Unique challenges faced by the clinical evaluation of dengue vaccines. Expert Rev Vaccine 10: 133–136.
[12]  Thomas SJ (2011) The necessity and quandaries of dengue vaccine development. J Infect Dis 203: 299–303.
[13]  Chackerian B (2007) Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 6: 381–390.
[14]  Liu W, Jiang H, Zhou J, Yang X, Tang Y, et al. (2010) Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties. Virus Genes 40: 53–59.
[15]  Tang Y, Jiang L, Zhou J, Yin Y, Yang X, et al. (2012) Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris.. Chin Med J 125: 1986–1992.
[16]  Kuwahara M, Konishi E (2010) Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens. Clin Vac Immunol 17: 1560–1566.
[17]  Wang PG, Kudelko M, Lo J, Siu LYL, Kwok KTH, et al. (2009) Efficient assembly and secretion of recombinant subviral particles of the four dengue serotypes using native prM and E proteins. PLOS One 4: e8325.
[18]  Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10: 787–796.
[19]  Yildiz I, Shukla S, Steinmetz NF (2011) Applications of viral nanoparticles in medicine. Curr Opin Biotechnol 22: 901–908.
[20]  Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100: 6986–6991.
[21]  Kuhn RJ, Zhang W, Rossman MG, Pletnev SV, Corver J, et al. (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108: 717–725.
[22]  Lindenbach BD, Thiel HJ, Rice CM (2007) Flaviviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors-in-chief. Fields of Virology, 5th edition. Philadelphia, PA: Wolters Kluwer and Lippincott Williams & Wilkins. pp. 1101–1152.
[23]  Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745–748.
[24]  Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, et al. (2010) Immature dengue virus: a veiled pathogen? PLOS Pathog 6: e1000718.
[25]  Men R, Bray M, Lai CJ (1991) Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased Immunogenicity in mice. J Virol 65: 1400–1407.
[26]  Gurramkonda C, Adnan A, G?bel T, Lünsdorf H, Ross A, et al. (2009) Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of hepatitis B surface antigen. Microb Cell Fact 8: 13.
[27]  Arora U, Tyagi P, Swaminathan S, Khanna N (2013) Virus-like particles displaying envelope domain III of dengue virus-type 2 induce virus-specific antibody response in mice. Vaccine 31: 873–878.
[28]  Macauley-Patrick S, Fazenda ML, McNeil B, Harvey LM (2005) Heterologous protein production using Pichia pastoris expression system. Yeast 22: 249–270.
[29]  Korrapati AB, Swaminathan G, Singh A, Khanna N, Swaminathan S (2012) Adenovirus delivered short hairpin RNA targeting a conserved site in the 5’ non-translated region inhibits all four serotypes of dengue viruses. PLOS Negl Trop Dis 6: e1735.
[30]  Kraus AA, Messer W, Haymore LB, de Silva AM (2007) Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Micribiol 45: 3777–3780.
[31]  Batra G, Raut R, Dahiya S, Kamran N, Swaminathan S, et al. (2010) Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies. J Virol Meth 167: 10–16.
[32]  Martin NC, Pardo J, Simmons M, Tjaden JA, Widjaja S, et al. (2006) An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies. J Virol Methods 134: 74–85.
[33]  Arora D, Chauhan A, Khanna N (1998) Easy PCR screening of Pichia pastoris transformants. Cell Mol Biol Lett 3: 21–24.
[34]  Batra G, Gurramkonda C, Nemani SK, Jain SK, Swaminathan S, et al. (2010) Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris. J Biosci Bioengg 110: 408–414.
[35]  Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E (2006) Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80: 10208–10217.
[36]  Bisht H, Chugh DA, Raje M, Swaminathan S, Khanna N (2002) Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent imunogen. J Biotechnol 99: 97–110.
[37]  Zhao Q, Wang Y, Freed D, Fu TM, Gimenez JA, et al. (2006) Maturation of recombinant hepatitis B virus surface antigen particles. Human Vaccines 2: 174–180.
[38]  Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, et al. (2007) Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81: 12816–12826.
[39]  Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai school children: a randomised, controlled phase 2b trial. Lancet 380: 1559–1567.
[40]  Sugrue RJ, Fu J, Howe J, Chan YC (1997) Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles. J Gen Virol 78: 1861–1866.
[41]  Valdés I, Hermida L, Zulueta A, Martín J, Silva R, et al. (2007) Expression in Pichia pastoris and immunological evaluation of a truncated dengue envelope protein. Mol Biotechnol 35: 23–30.
[42]  Hermida L, Rodríguez R, Lazo L, López C, Márquez G, et al. (2002) A recombinant envelope protein from dengue virus purified by IMAC is bioequivalent with its immune-affinity chromatography purified counterpart. J Biotechnol 94: 213–216.
[43]  Guzmán MG, Rodríguez R, Rodríguez R, Hermida L, Alvarez M, et al. (2003) Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg 69: 129–134.
[44]  Lünsdorf H, Gurramkonda C, Adnan A, Khanna N, Rinas U (2011) Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the hepatitis B surface antigen. Microb Cell Fact 10: 48.
[45]  Kelly EP, Greene JJ, King AD, Innis BL (2000) Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18: 2549–2559.
[46]  Clements DE, Coller BG, Lieberman MM, Ogata S, Wang G, et al. (2010) Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28: 2705–2715.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133